A multiplexed, particle-based flow cytometric assay identified plasma matrix metalloproteinase-7 to be associated with cancer-related death among patients with bladder cancer

Cancer

Volumn 116, Issue 19, 2010, Pages 4513-4519

  Svatek, Robert S ^a   Shah, Jay B ^a   Xing, Jinliang ^a   Chang, David ^a   Lin, Jie ^a   McConkey, David J ^a   Wu, Xifeng ^a   Dinney, Colin P ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Bladder cancer; Matrix metalloproteinases; MMP 7; Plasma

Indexed keywords

GELATINASE A; GELATINASE B; INTERSTITIAL COLLAGENASE; MACROPHAGE ELASTASE; MATRILYSIN; NEUTROPHIL COLLAGENASE; STROMELYSIN; TUMOR MARKER;

ADULT; AGED; ARTICLE; BLADDER CANCER; CANCER MORTALITY; CANCER SURVIVAL; CAUSE OF DEATH; CLINICAL FEATURE; ENZYME BLOOD LEVEL; FEMALE; FLOW CYTOMETRY; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SURVIVAL RATE; SURVIVAL TIME; BLADDER TUMOR; BLOOD; EVALUATION STUDY; MIDDLE AGED; MORTALITY; PROCEDURES; PROGNOSIS; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; FEMALE; FLOW CYTOMETRY; HUMANS; MALE; MATRIX METALLOPROTEINASE 7; MIDDLE AGED; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL; URINARY BLADDER NEOPLASMS;

EID: 77957163734     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.25401     Document Type: Article

References (31)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2008. CA Cancer J Clin. 2008;58:71-96.
2. Stein JP, Lieskovsky G, Cote R, et al. Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients. J Clin Oncol. 2001;19:666-675. (Pubitemid 32120143)
3. Shabsigh A, Bochner BH. Use of nomograms as predictive tools in bladder cancer. World J Urol. 2006;24:489-498. (Pubitemid 44782303)
4. Karakiewicz PI, Shariat SF, Palapattu GS, et al. Nomogram for predicting disease recurrence after radical cystectomy for transitional cell carcinoma of the bladder. J Urol. 2006; 176(4 pt 1):1354-1361; discussion 61-62.
5. Bochner BH, Kattan MW, Vora KC. Postoperative nomogram predicting risk of recurrence after radical cystectomy for bladder cancer. J Clin Oncol. 2006;24:3967-3972. (Pubitemid 46630745)
6. Svatek RS, Jeldres C, Karakiewicz PI, et al. Pre-treatment biomarker levels improve the accuracy of post-prostatectomy nomogram for prediction of biochemical recurrence. Prostate. 2009;69:886-894.
7. Kramer MW, Golshani R, Merseburger AS, et al. HYAL-1 hyaluronidase: a potential prognostic indicator for progression to muscle invasion and recurrence in bladder cancer. Eur Urol. 2010;57:86-93.
8. Vrooman OP, Witjes JA. Molecular markers for detection, surveillance and prognostication of bladder cancer. Int J Urol. 2009;16:234-243.
9. Egeblad M, Werb Z. New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer. 2002;2: 161-174. (Pubitemid 37328786)
10. Sternlicht MD, Werb Z. How matrix metalloproteinases regulate cell behavior. Annu Rev Cell Dev Biol. 2001;17: 463-516. (Pubitemid 33096184)
11. Shiomi T, Okada Y. MT1-MMP and MMP-7 in invasion and metastasis of human cancers. Cancer Metastasis Rev. 2003;22:145-152. (Pubitemid 36561054)
12. Vasala K, Kuvaja P, Turpeenniemi-Hujanen T. Low circulating levels of ProMMP-2 are associated with adverse prognosis in bladder cancer. Tumour Biol. 2008;29:279-286.
13. Vasala K, Paakko P, Turpeenniemi-Hujanen T. Matrix metalloproteinase- 2 immunoreactive protein as a prognostic marker in bladder cancer. Urology. 2003;62:952-957. (Pubitemid 37421256)
14. Vasala K, Paakko P, Turpeenniemi-Hujanen T. Matrix metalloproteinase- 9 (MMP-9) immunoreactive protein in urinary bladder cancer: a marker of favorable prognosis. Anticancer Res. 2008;28:1757-1761.
15. Wallard MJ, Pennington CJ, Veerakumarasivam A, et al. Comprehensive profiling and localisation of the matrix metalloproteinases in urothelial carcinoma. Br J Cancer. 2006; 94:569-577. (Pubitemid 43289762)
16. Greene FL. Urinary bladder. In: Greene FL, Page DL, Fleming ID, et al, eds. AJCC Cancer Staging Manual. 6th ed. New York: Springer-Verlag; 2002:301-323.
17. Epstein JI, Amin MB, Reuter VR, Mostofi FK. The World Health Organization/International Society of Urological Pathology consensus classification of urothelial (transitional cell) neoplasms of the urinary bladder. Bladder Consensus Conference Committee. Am J Surg Pathol. 1998;22:1435-1448.
18. Cox D. Regression models and life tables (with discussion). J R Stat Soc B. 1972;34:187-220.
19. Harrell FE Jr, Lee KL, Mark DB. Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med. 1996;15:361-387.
20. Kaplan E, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457-481.
21. Guan KP, Ye HY, Yan Z, Wang Y, Hou SK. Serum levels of endostatin and matrix metalloproteinase-9 associated with high stage and grade primary transitional cell carcinoma of the bladder. Urology. 2003;61:719-723. (Pubitemid 36384961)
22. Ozdemir E, Kakehi Y, Okuno H, Yoshida O. Role of matrix metalloproteinase-9 in the basement membrane destruction of superficial urothelial carcinomas. J Urol. 1999;161: 1359-1363.
23. Gerhards S, Jung K, Koenig F, et al. Excretion of matrix metalloproteinases 2 and 9 in urine is associated with a high stage and grade of bladder carcinoma. Urology. 2001;57: 675-679.
24. Staack A, Badendieck S, Schnorr D, Loening SA, Jung K. Combined determination of plasma MMP2, MMP9, and TIMP1 improves the non-invasive detection of transitional cell carcinoma of the bladder. BMC Urol. 2006;6:19.
25. Ii M, Yamamoto H, Adachi Y, Maruyama Y, Shinomura Y. Role of matrix metalloproteinase-7 (matrilysin) in human cancer invasion, apoptosis, growth, and angiogenesis. Exp Biol Med (Maywood). 2006;231:20-27.
26. Ueno H, Yamashita K, Azumano I, Inoue M, Okada Y. Enhanced production and activation of matrix metalloproteinase- 7 (matrilysin) in human endometrial carcinomas. Int J Cancer. 1999;84:470-477.
27. Mori M, Barnard GF, Mimori K, Ueo H, Akiyoshi T, Sugimachi K. Overexpression of matrix metalloproteinase-7 mRNA in human colon carcinomas. Cancer. 1995;75(6 suppl):1516-1519.
28. Yamashita K, Azumano I, Mai M, Okada Y. Expression and tissue localization of matrix metalloproteinase 7 (matrilysin) in human gastric carcinomas. Implications for vessel invasion and metastasis. Int J Cancer. 1998;79:187-194.
29. Thrailkill KM, Moreau CS, Cockrell G, et al. Physiological matrix metalloproteinase concentrations in serum during childhood and adolescence, using Luminex Multiplex technology. Clin Chem Lab Med. 2005;43:1392-1399.
30. Svatek RS, Skinner E, Shariat SF, et al. Evidence-based gender related outcomes after radical cystectomy: results of a large multicenter study. Am Urol Assoc. 2009.
31. Karakiewicz PI, Hutterer GC. Predicting outcomes in patients with urologic cancers. Curr Opin Support Palliat Care. 2007;1:153-168.